To assess baseline characteristics of a cohort of young men with erectile dysfunction (ED) but no identifiable organic cause and to evaluate the efficacy of our treatment algorithm.
Introduction
Erectile dysfunction (ED) in the older man is commonly seen in a typical urology practice. It affects an estimated 20% of men aged > 40 years, with an incidence four times higher for men in their 70s compared with men in their 20s [1, 2] . With such high prevalence, an abundance of research has been reported on effectively evaluating and treating ED in this older cohort of patients [3, 4] . Interestingly, the clinical presentation of young men with ED has been increasing, with 25% of new cases of ED occurring in men aged < 40 years [5] ; therefore, awareness of ED in young men is increasing among the urological community.
As these young and healthy men present to the urologist, there is an increased interest in the urological community to investigate various aetiologies [6, 7] . Long-standing and successful treatment protocols exist for ED that is caused by vascular, neurogenic, endocrine and structural abnormalities [4, 8, 9] ; however, there is a paucity of literature describing the possible pathogenesis of ED in the otherwise healthy young man, posing a challenge to the treating urologist. One such theory describes increased sympathetic tone as the organic cause of 'psychogenic' ED [10] . It is thought that inhibition of the spinal erection centre attributable to exaggerated normal inhibition, or increased sympathetic outflow, results in increased penile smooth muscle tone and poor vasodilation [11] . As psychological stressors have been shown to instigate neuroendocrine changes in the brain, it is no surprise that a heightened sympathetic response may diminish erectile capacity [6, 11] .
With an increased awareness and interest in the population of young, otherwise healthy men with ED, it is important for clinicians to have a comprehensive understanding of appropriate management options for these patients [6] . Current literature, however, continues to focus on the older man, and thus may be limited in its applicability to a younger man with suspected psychogenic inhibition. As such, a lack of evidence weakens a urologist's confidence in treating these young patients. In the present paper, we aim to review our cohort of young healthy men with ED and evaluate the efficacy our treatment approach.
Materials and Methods
All patients presenting to our centre with a chief complaint of ED are asked to complete a detailed questionnaire that solicits information regarding medical, social and sexual history, as well as the International Index of Erectile Function (IIEF) questionnaire. Our initial priority is to develop a comprehensive understanding of the patient's sexual dysfunction. The office evaluation begins with a thorough sexual, genitourinary, surgical, medical and psychosocial history. This is followed by a physical examination, including a detailed male genitourinary examination to exclude any obvious structural abnormalities, such as Peyronie's plaques or palpable corporal fibrosis. All patients subsequently undergo biothesiometry to assess penile sensitivity indirectly. Penile duplex ultrasonography with vasoactive injection is performed for those previously treated with and who have failed phosphodiesterase type 5 (PDE-5) inhibitors. As part of an endocrine evaluation, a morning free and total serum testosterone assessment is ordered. Patients should also have basic laboratory studies completed within the past 6 months including complete blood count, basic metabolic panel, and fasting glucose and lipid panel. This represents our standard initial evaluation of all men presenting with ED.
For patients with initial evaluations that failed to reveal any potential organic cause, our standard treatment approach begins by introducing the possibility of a 'psychogenic' root to their condition, with care taken not to use insensitive or dismissive language. We inform the patient that the CNS has been shown to inhibit erectile response without cognitive awareness by the patient [10, 12] . Patient education is followed by the prescription of a nightly dose of 5 mg tadalafil (Cialis â ; Eli Lilly, Indianapolis, IN, USA), with the option of additional 'boosters' up to 20 mg tadalafil as needed 1-2 h prior to sexual encounters. Patients are then instructed to follow up in 8 weeks, at which point erectile and sexual function are reassessed. In patients who have obtained a sufficient response, tadalafil is titrated down, with the anticipation of full pharmacological rehabilitation. In those with inadequate response and/or impaired confidence in their sexual function, the addition of psychosexual therapy is strongly recommended. If the patient is willing, a referral is made to a clinical psychologist who specializes in psychosexual therapy. Pending a sub-optimal response to both pharmacological and psychosexual therapy, patients with refractory ED are further evaluated with penile duplex ultrasonography with intracavernosal vasoactive injection to evaluate penile vascular integrity and assess their physical as well as psychological response to intracavernosal injections. These refractory patients are then offered more invasive treatment options, including intracavernosal injections, vacuum therapy, intra-urethral pharmacotherapy or the placement of a prosthesis. Nonetheless, we have yet to place a penile prosthesis in any of these men.
In the present retrospective chart review, we sought to evaluate our above treatment algorithm for men aged < 40 years with no identifiable organic cause to their ED. Thus, after obtaining institutional review board approval, we searched our patient data repository for all men aged < 40 years who were seen in our tertiary referral centre with a diagnosis of ED between March 2010 and August 2016. A total of 185 men met our initial inclusion criteria, of whom 73 successfully completed the initial intake questionnaire and had no identifiable organic cause of their ED in the patient record.
After a minimum of 6 months from initial evaluation, the men were contacted via telephone or e-mail and asked to complete either a paper or online version of the same questionnaire that was completed at their initial presentation. Additional questions included inquiries into current sexual function, current satisfaction with sexual function, and any adopted changes to the prescribed therapy. Thirty-three men completed the follow-up questionnaire in its entirety. Each variable was evaluated individually, comparing initial data with post-therapy data via a two-tailed t-test to determine the efficacy of our proposed treatment algorithm.
Results
Seventy-three men with no identifiable organic cause of ED successfully completed our initial questionnaire and are included in our baseline characteristics assessment. Pertinent patient demographics and results from initial patient evaluations are provided in Table 1 . The mean (range) age of this cohort was 31.9 (18-39) years, with a mean (range) body mass index of 23.57 (18.83-34.46) kg/m 2 . Five men (6.8%) reported current, everyday smoking, while six (8.2%) were former smokers. Forty-six men (63%) indicated current involvement in a relationship, either marriage or a long-term partner. Seventeen men (23.3%) reported a history of anxiety or depression. Twenty-four men (32.9%) underwent penile duplex ultrasonography because of suspicion of a vascular or structural component to their ED. All men received a minimal dose of vasoactive intracavernosal injection between 0.05 and 0.10 mL of Trimix (prostaglandin E 10 mcg/ papavarine 30 mg/Phentolamine 1 mg per mL) and obtained either a 9/10 or 10/10 strong erection within 10 min, without any evidence of any clinically significant arterial insufficiencies or venous leaks. Biothesiometric results were tabulated via a sensitivity threshold ratio between the middorsal glans and the left index finger; the mean (range) ratio in this cohort of men was 1.58 (0.79-2.73). Endocrine evaluation showed a mean morning total testosterone level of 439.8 ng/dL and a mean morning free testosterone level of 85.9 ng/dL. Thirty-six men (49%) had undergone some form of treatment for their ED prior to presentation to our clinic, with all 36 men undergoing previous PDE-5 inhibitor therapy, and three (8.3%) having progressed to intracavernosal injections.
Subjective patient-reported descriptors of their erectile function are provided in Table 2 . Sixty-two men (85%) reported problems obtaining an erection, while 72 (98%) had problems maintaining an erection. Twenty-one men (29%) reported that they considered their ED to be associated with a specific event such as personal or familial illnesses, or an acute physically/psychologically taxing event. Fifty-two men (71%) reported experiencing morning erections and 49 men (67%) noted frequently awakening at night with erections. Twenty-six men (36%) reported diminished sexual desire. Seventy-two men (98%) were able to ejaculate, while 20 (27%) reported difficulties with premature ejaculation. Overall, 52 men (71%) reported that they were still able to produce an erection sufficient for penetration under some circumstances, usually in < 20% of attempts. On average, IIEF scores were in the mild to moderate range for erectile function (mean 13.3, range 1-27), orgasmic function (mean 6.2, range 0-10), sexual desire (mean 6.3, range 2-10), and intercourse satisfaction (mean 7.3, range 0-15). Overall satisfaction, however, was in the moderate range (mean 4.5, range 1-10).
Thirty-three men completed the follow-up questionnaire in its entirety. Mean post-treatment IIEF scores showed a significant improvement (vs pre-treatment IIEF scores) in erectile function (18.8 vs 13.3; P < 0.01), orgasmic function (7.7 vs 6.2; P = 0.01), and overall satisfaction (6.1 vs 4.5; P < 0.01). Assessments of improvement in Sexual desire and intercourse satisfaction did not reach statistical significance (Fig. 1) . Subjective responses regarding current erectile function, in addition to current treatment practices among the respondent cohort, are detailed in Table 3 . The mean (range) age of responders was 32.7 (22-39) years. Post-therapy, 14 men (42%) reported problems obtaining an erection, 23 men (70%) reported problems maintaining an erection, and 19 men (58%) reported satisfaction with their current erectile function. All 33 men indicated no problems with ejaculatory function, with the majority (79%) being able to ejaculate via intercourse, and the entirety (100%) able to ejaculate via masturbation. Four men (12.1%) experienced premature ejaculation on follow-up, which was alleviated with a prescription of Promescent â (Absorption Pharmaceuticals, Huntington Beach, CA, USA). Twenty-two men (66%) found increased satisfaction in their sexual relationships as a result of therapy.
Current treatment, however, was variable among respondents. Eleven men (33.3%) achieved complete pharmacological rehabilitation on titration of daily tadalafil and were no longer receiving any form of treatment. Fourteen men (42.4%) reported current daily PDE-5 inhibitor therapy, while three men (9.1%) reported daily therapy with the requirement of a booster prior to sexual activity. Four men (12.1%) with ED refractory to PDE-5 inhibitor therapy reported the use of intracavernosal injections. Of the 33 respondents, four (12.1%) continued with psychosexual therapy.
Discussion
A thorough initial evaluation is imperative for determining the aetiology of ED and, as detailed in Table 1 , the present cohort of men failed to reveal any identifiable organic cause to their presenting complaint. We performed in-office biothesiometry to indirectly assess the penile sexual sensitivity of these men, as increased sensory thresholds have been shown to be directly related to ED [13, 14] . Biothesiometric results revealed a mid-dorsal glans/left index finger sensitivity threshold ratio of 1.58 (range 0.78-2.72), indicating largely normal penile sensation with no sensory deficiency contributing to the ED of these men [14] .
Duplex ultrasonography with a vasoactive agent was administered to 24 men on initial evaluation whose history suggested the possibility of a vascular aetiology to their ED. All penile duplex ultrasonography performed was found to be normal with an appropriate and adequate erectile response and vascular parameters with minimal intracavernosal vasoactive injection, ruling out vasculogenic aetiologies [15] .
The relationship of serum androgen levels and erectile function has proven complex and is not fully understood. Testosterone is essential for the male sexual response; however, an independent association between ED and testosterone levels has not been noted. That is, a linear relationship does not exist between testosterone concentration and erectile function [16] . Nonetheless, a threshold concentration appears necessary, as outright low testosterone qualifying as hypoandrogenism has been shown to be significantly related to ED [17] . As such, it is imperative to exclude androgen deficiency as a possible contributing factor in the presentation of these young men, and a mean serum testosterone level of 439.8 ng/dL largely eliminates this concern. No man in the present cohort was found to have sub-optimal testosterone levels, and thus none was prescribed any form of testosterone replacement therapy. Indeed, no organic aetiology in these men was identifiable, allowing the determination of a likely psychogenic component to their complaint. This assessment was furthermore supported by the majority of men self-reporting frequent episodes of both nocturnal and morning erections. Interestingly, the assertion by Reed-Maldonado et al. [6] that psychiatric comorbidities are more prevalent in men with proposed psychogenic ED holds true in the present cohort, as a prevalence of 23% is far above the national age-matched average [18] . One-third of the men experienced full return of erectile function with no current need for medication. It appears that tadalafil alone was successful in rehabilitating 33% of these men, allowing a continued erectile response. The majority (52%) of our cohort continue to take daily tadalafil, indicating a beneficial effect with pharmacological therapy, but not complete rehabilitation. A minority of patients (12%) experienced ED refractory to PDE-5 inhibitors and progressed to intracavernosal injections to achieve an adequate response.
Our treatment algorithm for young men with no organic cause to their ED significantly improved patients' IIEF domains for erectile and orgasmic function, as well as overall satisfaction with sexual function. Sexual desire and satisfaction with intercourse did not significantly improve, which may be attributable to the use of a PDE-5 inhibitor as a core component of our treatment protocol, as PDE-5 inhibitors have not been shown to be effective at improving sexual desire or satisfaction [19] . Significant improvement in the remaining three IIEF domains, however, probably reflects an appreciable positive effect on the patient's sexual health, thus lending credence to the efficacy of our approach.
The development of our methodology centres on the individual effectiveness of each component, in hopes of synergistic effects when combined into a single algorithm. The combination of a comprehensive interview, physical examination and in-office diagnostic studies allows a thorough and complete assessment. These interactions, in addition to the follow up in-office discussions, lead to a more genuine and confidence-building patient-physician relationship. Since a comprehensive physical examination and thorough patient education have been shown to be directly correlated with patient satisfaction and subsequent treatment adherence, the completion of this inclusive initial encounter is imperative to our algorithm's success [20, 21] . As 49% of our patients had failed prior treatments, it is crucial that the initial encounter provides the patient comfort in knowing that his ED is being fully investigated and is being treated accordingly.
In cases of non-organic, psychogenic inhibition resulting in ED, the use of a PDE-5 inhibitor as an initial treatment approach warrants justification. Reed-Maldonado et al. [6] described a syndrome in young men with 'psychogenic' ED where they have excessive sympathetic outflow, which increases penile smooth muscle tone, and prevents sufficient relaxation for sustained tumescence; thus, they propose using nightly low-dose a-adrenergic blockade to aid in smooth muscle relaxation. There is evidence that PDE-5 inhibitors induce genitourinary smooth muscle relaxation [22] . Moreover, nightly tadalafil can psychologically rehabilitate these patients by increasing the frequency and rigidity of spontaneous nocturnal and morning erections [23] . The objective is to allow patients to regain confidence, reduce stress, and ultimately lessen the inhibitory adrenergic tone that had originally contributed to their ED. These positive effects can increase self-esteem and satisfaction in sexual relationships, reinforcing the patient's trust and confidence in the treating urologist. With this increase in patient selfconfidence, we can begin to titrate off tadalafil as the excessive sympathetic tone associated with sexual stimuli wanes.
We also believe that psychosexual therapy is a critical adjunct treatment approach for patients who are unsatisfied with their erectile function after initiating nightly tadalafil. The efficacy of psychotherapy in ED has been debated, with individual studies showing variable results; however, meta-analysis revealed a significant improvement in erectile function via combination-therapy of a PDE-5 inhibitor and psychotherapy sessions, while also resulting in improved treatment adherence [24] . Considering the significant psychogenic aetiology in these young men, use of this combination approach is intuitive. Interestingly, however, only four men (12%) pursued a trial of psychosexual therapy. It is likely that the majority of these men found sufficient rehabilitation via nightly tadalafil and thus did not consider further progression of therapy necessary, but it is also possible that the perceived stress of an interpersonal discussion regarding such a sensitive topic stood as a barrier to seeking care through a sex therapist. Another barrier is the often high out-of-pocket cost, as many men reported that psychotherapy is not covered by their respective health insurance providers. As such, in cases of persistently refractory ED in the unwilling patient, thorough patient education regarding the role, and documented efficacy of this adjuvant component may be necessary to prompt an initial appointment.
The core components of our treatment protocol have been shown to significantly improve erectile response; however, a detailed discussion regarding more invasive alternatives is needed with patients who fail to respond to these interventions. The use of intracavernosal injections and urethral suppositories has elicited positive results for ED refractory to PDE-5 inhibitors and is thus an appropriate next step in addressing these challenging cases [25] . The present study included four men whose ED proved refractory to oral therapy, and who ultimately regained functionality via intracavernosal injections. Men who still fail to regain their erectile functionality after the administration of local pharmacological agents are then considered for the placement of a penile prosthesis. With high satisfaction rates, penile prosthesis stands as the last-resort option for the refractory patient [26] . Nevertheless, no penile prosthesis was placed in the cohort of men described here.
It is important to understand the deleterious effects of ED in the younger man. Studies have indicated that ED is multifaceted in its detriment to the patient. Apart from the obvious impact on one's reproductive capacity, men with ED are likely to struggle with depression and feelings of emasculation and inadequacy [27] . Socially, men with ED have reported a significant decline in the quality of intimate relationships, with many having concerns that their inability to achieve an erection will result in the termination of the relationship. Additionally, day-to-day relationships have been shown to suffer, as an inability to overcome ED-associated anxiety, depression and emasculation impede one's social confidence and morale [27, 28] . One would suspect these sentiments may negatively affect young men to a larger degree, as they prioritize career advancement and the development and maintenance of intimate relationships. Certainly, achieving these goals becomes more challenging as a result of the psychologically destructive effects of ED [28, 29] .
As such, any modest improvement in sexual function can have a significant positive impact on a young man's emotional and psychological well-being and lessen emotional performance-related stress. Moreover, an improved erectile response may reduce anxiety levels associated with the prospect of failure, allowing a more consistent erectile ability and heightened overall sexual satisfaction. Indeed, with 66% of respondents indicating heightened satisfaction in their sexual relationships, the improvement in erectile function experienced by these patients had a noticeably beneficial emotional effect.
The present study has several limitations. Most notably, the sample size was limited, as was the follow-up period. Our follow-up questionnaire response rate was < 50%. This can be partly attributed to several inherent factors in a cohort of healthy young men, such as moving away, changing of address or contact information, non-compliance or refusal to participate. As a result of the low response rate, this study is prone to non-response bias. Moreover, details on actual sexual activity with and without PDE-5 inhibitors were not captured. Future studies should attempt to address these pitfalls with the administration of follow-up questionnaires during in-office follow-up encounters. This would probably eliminate the biases that may have influenced our results.
In conclusion, we have shown that use of our proposed algorithm and treatment approach in the treatment of healthy young men with suspected ED of non-organic origin results in significant improvements in multiple domains of erectile function. These results should provide treating urologists with confidence in treating this potentially challenging cohort of men, ultimately improving sexual function in those seeking care.
